Due to interacting metabolic, renal and cardiovascular dysfunction, cardiovascular-kidney-metabolic syndrome is difficult to treat. Here, the authors show a urea-responsive, kidney-targeted nanocarrier enables site-specific SGLT2 inhibition, restores cardiorenal metabolism and improves efficacy.
- Xuechun Ren
- Di Gao
- Zhe Yang
